Author(s): Demet YILDIZ | Sevda ERER ÖZBEK | Mehmet ZARİFOĞLU | Mustafa BAKAR | Necdet KARLI | Nevin TÜRKEŞ
Journal: Nöropsikiyatri Arşivi
ISSN 1300-0667
Volume: 47;
Issue: 1;
Start page: 47;
Date: 2010;
VIEW PDF
DOWNLOAD PDF 
Original page
Keywords: Parkinson’s Disease | mild dementia | neuropsychological test
ABSTRACT
Objective: In this study, we aimed to evaluate the cognitive functions in Parkinson’s disease patients with using neuropsychological assessment and to identify its clinical correlates in Parkinson’s disease.Methods: Thirty-three patients with idiopatic Parkinson’s disease (PD) and 16 control subjects who are being followed by the Neurology Outpatient Clinic were included in this study. After evaluation of the cognitive functions by using MMSE (Mini-Mental State Examination) test, all cases with PD were divided into 2 groups: normal and mild dementia. Glucose, hemoglobin, TSH, cholesterol, homocysteine, vitamin B12 and folic acid levels were examined. Depression was excluded using geriatric depression test.Results: Memory, attention, verbal and visual fluency were evaluated with neuropsychological tests. Both Parkinson’s groups demonstrated poor performance compared to the control group, but mental fluency, planning, verbal-visual memory, results of Trail Making Test A and counting backwards were worse in the mild dementia group. Significant difference was found between control and mild dementia groups by orientation, mental control, abstract thinking, logical memory and visuospatial tests. According to Luria’s drawing test, mental fluency, and stroop, planning and RAVEN tests, poor performance was observed in the mild dementia group when compared with the other two groups. Conclusion: MMSE test may be used to diagnose dementia in PD patients because of the correlation of MMSE scores and the other memory tests. However, due to disorders detected in verbal-visual memory, mental fluency and planning tests in patients with MMSE scores above 23, the importance of neuropsychological tests is emphasized in determining subclinical cognitive dysfunction in PD patients. (Archives of Neuropsychiatry 2010; 47: 47-52)
Journal: Nöropsikiyatri Arşivi
ISSN 1300-0667
Volume: 47;
Issue: 1;
Start page: 47;
Date: 2010;
VIEW PDF
DOWNLOAD PDF Original pageKeywords: Parkinson’s Disease | mild dementia | neuropsychological test
ABSTRACT
Objective: In this study, we aimed to evaluate the cognitive functions in Parkinson’s disease patients with using neuropsychological assessment and to identify its clinical correlates in Parkinson’s disease.Methods: Thirty-three patients with idiopatic Parkinson’s disease (PD) and 16 control subjects who are being followed by the Neurology Outpatient Clinic were included in this study. After evaluation of the cognitive functions by using MMSE (Mini-Mental State Examination) test, all cases with PD were divided into 2 groups: normal and mild dementia. Glucose, hemoglobin, TSH, cholesterol, homocysteine, vitamin B12 and folic acid levels were examined. Depression was excluded using geriatric depression test.Results: Memory, attention, verbal and visual fluency were evaluated with neuropsychological tests. Both Parkinson’s groups demonstrated poor performance compared to the control group, but mental fluency, planning, verbal-visual memory, results of Trail Making Test A and counting backwards were worse in the mild dementia group. Significant difference was found between control and mild dementia groups by orientation, mental control, abstract thinking, logical memory and visuospatial tests. According to Luria’s drawing test, mental fluency, and stroop, planning and RAVEN tests, poor performance was observed in the mild dementia group when compared with the other two groups. Conclusion: MMSE test may be used to diagnose dementia in PD patients because of the correlation of MMSE scores and the other memory tests. However, due to disorders detected in verbal-visual memory, mental fluency and planning tests in patients with MMSE scores above 23, the importance of neuropsychological tests is emphasized in determining subclinical cognitive dysfunction in PD patients. (Archives of Neuropsychiatry 2010; 47: 47-52)
